Results 181 to 190 of about 128,678 (309)
Multimodality imaging in hypertrophic cardiomyopathy. [PDF]
Kim J, Lee SC.
europepmc +1 more source
The Phospholamban (PLN) R9C mutation reduces SERCA2a binding, increasing calcium recycling and baseline contractility. However, the excess of free PLN promotes pentamer formation, limiting phosphorylation and blunting β‐adrenergic signaling. Under cardiac stress, enhanced functional demands overwhelm proteostasis in PLN R9C cells, leading to misfolded ...
Qi Yu +10 more
wiley +1 more source
Correction: Mechanisms of metabolic transition in hypertrophic cardiomyopathy. [PDF]
Tan C, Guo Z, Zhou J, Yuan W.
europepmc +1 more source
ABSTRACT Costello syndrome (CS) is a rare dominant HRAS RASopathy characterized by curly hair, cardiac abnormalities, craniofacial anomalies, and developmental delay. HRAS codon 58, 59, and 60 variants are associated with milder phenotypes. We describe a three‐generation family with a previously unreported heterozygous HRAS variant c.175G>A (p.Ala59Thr)
Nikole Rautiainen +10 more
wiley +1 more source
Indications for Surgery in Obstructive Hypertrophic Cardiomyopathy
Mark V. Sherrid
doaj +1 more source
Case Report: Hypertrophic cardiomyopathy meets left ventricular hypertrabeculation: from mixed cardiomyopathy to hypertrophic cardiomyopathy with hypertrabeculation. [PDF]
Li Y +5 more
europepmc +1 more source
A Genotype-phenotype Taxonomy of Hypertrophic Cardiomyopathy
Lara Curran +26 more
openalex +1 more source
Clinical characteristics and long‐term outcomes in patients with apical hypertrophic cardiomyopathy [PDF]
Meng Guo +3 more
openalex +1 more source
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo +22 more
wiley +1 more source

